抑制ACE的三LL-X的结构-活性关系和分子相互作用机制
Cuicui Yang1, Mengmeng Cai1, Zhengkun Ma1
1Guangxi Key Laboratory for Polysaccharide Materials and Modifications, School of Chemistry and Chemical Engineering, Guangxi Minzu University, Nanning 530006, China.
Bioorganic chemistry
|August 30, 2025
概括
这种C端氨基酸显著影响血管转化酶 (ACE) 抑制性活性. 在Leu-Leu-Tyr中用氨酸或氨酸取代氨酸降低了ACE抑制,突显了氨酸在抗高血压设计中的关键作用.
科学领域:
- 生物化学
- 药理学
- 药物发现
背景情况:
- 血管激素转化酶 (ACE) 抑制剂对于治疗高血压至关重要.
- 了解ACE抑制的分子相互作用有助于开发抗高血压药物.
- 由素衍生的三蛋白Leu-Leu-Tyr (LLY) 具有抑制ACE的特性.
研究的目的:
- 研究C端氨基酸替代对抑制ACE活性的影响.
- 将新变体 (LLF,LLP) 的ACE抑制动力学和结合机制与LLY进行比较.
- 为设计有效的ACE抑制提供理论基础.
主要方法:
- 新型变体Leu-Leu-Phe (LLF) 和Leu-Leu-Pro (LLP) 的合成
- 对ACE抑制活性进行测定 (IC50测定).
- 酶动力学分析 (Lineweaver-Burk图).
- 分子对接和分子动力学模拟.
- 分析-ACE相互作用和蛋白质结构变化的多谱技术.
主要成果:
- 与LLY (IC50 = 44. 16 ± 2. 45 μM) 相比,LLF (IC50 = 168. 57 ± 5. 11 μM) 和LLP (IC50 = 96. 64 ± 2. 93 μM) 的ACE抑制活性显着较低.
- 与LLY一样,LLF和LLP是非竞争性的ACE抑制剂.
- 与LLF和LLP相比,LLY诱导了ACE中的更大的蛋白质结构障碍,与更高的抑制活性相关.
结论:
- 在LLY中的C端氨酸对其强大的ACE抑制活性至关重要.
- C端氨基酸特性显著影响三ACE抑制剂的疗效.
- 这项研究为新型抗高血压的合理设计提供了基础见解.
相关概念视频
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
645
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
645
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.2K


